Product Liability Lawyer Blog

March 15, 2014

Different Surgeries Offer Successful Alternatives to Transvaginal Mesh

Female incontinence is an embarrassing, complicated disorder, not uncommon for older women or those who suffered injury during childbirth. New research published and highlighted in an article by Tech Times, has revealed that female incontinence can now be treated by two effective surgeries, an alternative to transvaginal mesh implants, medical devices that have led to painful complications for thousands of women nationwide.

Female incontinence is sometimes caused by pelvic organ prolapse. In the past few decades pelvic organ prolapse has been treated with transvaginal mesh resulting in long-term damage and injury to patients. Our Boston transvaginal mesh attorneys are dedicated to protecting the rights of women injured by defective medical products, including TVM. We are also committed to keeping patients aware of the potential risks associated with transvaginal mesh.
Continue reading

March 13, 2014

TVM Company Facing Falling Revenues & Legal Trouble

by Jeffrey S. Glassman

In 2011, Endo Pharmaceuticals bought American Medical Systems (AMS) for $2.9 billion. When Endo bought AMS, Endo become responsible for any potential legal liability associated with products that AMS had sold to consumers. Unfortunately, this turned out to be a big issue since American Medical Systems was one of the primary manufacturers of transvaginal mesh products.

TVM products made by a variety of manufacturers have caused very serious problems for patients, including severe pain, erosion of the mesh and recurrent pelvic organ prolapse (one of the very conditions the mesh was designed to treat). Thousands of lawsuits have been filed, and Endo reportedly set aside an additional $316 million for its “product liability reserve” to deal with vaginal mesh lawsuits. Plaintiffs who were harmed by the AMS products should consult with an experienced Boston transvaginal mesh lawyer for information on whether they could potentially obtain settlement funds or other damages for injuries.
Continue reading

March 9, 2014

Judge in TVM Cases Addresses Lien Resolution

by Jeffrey S. Glassman

More than 40,000 plaintiffs who have filed transvaginal mesh claims are suffering serious complications associated with the use of surgical mesh products. Many of the plaintiffs who experienced these complications have already been forced to undergo revision surgeries and to have other expensive medical treatments performed to resolve complications from failed surgical mesh products. Unfortunately, many of these thousands of women have not yet been paid by the companies that produced the mesh.

When plaintiffs are injured by a product and undergo medical treatment as a result, their health insurers often pay for the bills. Then, when the plaintiff recovers compensation in a personal injury or product liability lawsuit, the health insurer is often entitled to be reimbursed for expenses and outlays. A Boston transvaginal mesh lawyer can help victims injured by TVM products to understand the impact of these healthcare liens on the outcome of their case, since the liens must be addressed. Recently, for example, the court presiding over a large multi-district TVM case in West Virginia has issued a pretrial order appointing a Lien Resolution Administrator.
Continue reading

March 7, 2014

Long Recovery Makes Replacement-Hip Failure Especially Tragic

by Jeffrey S. Glassman

Patients who opt for replacement hip or knee joints have a long road to recovery after the procedure. While many factors go into the decision of whether to get elective joint replacement, those who have the operation do so because they want to increase mobility and be able to do more with their lives. However, doctors recommend other types of treatments like losing weight or exercising to strengthen the muscles around the joints because the recovery process for surgical joint replacement can be intensive.

When a patient does decide to undergo a joint replacement procedure, the full process of healing the soft tissue and bone could take longer than a year. After the time, expense and recovery process, patients deserve to enjoy the benefits that they hoped for when undergoing the surgery. Unfortunately, far too often, this does not happen because patients instead find themselves coping with serious complications and with the potential need for revision surgery.
Continue reading

March 4, 2014

Safety of Testosterone Replacement Products Called Into Question

by Jeffrey S. Glassman

Middle aged men and older men in the U.S. are being prescribed testosterone replacement therapy in ever increasing numbers. Low testosterone can lead to impaired sexual function, fat distribution problems, weakening bone density; and perhaps even a higher risk of heart disease.

Products like GlaxoSmithKline’s Testim; Eli Lily’s Axiron, and AbbVie’s AndroGel are three of the testosterone replacement products approved by the U.S. Food and Drug Administration. Unfortunately, manufacturers of some of these products have found themselves accused of hiding risks. AbbVie, for example, has been sued because men who used AndroGel claim they experienced unexpected side effects due to the low-T treatment. Several of the plaintiffs experienced heart attacks, while others had strokes.
Continue reading

March 3, 2014

Lipitor Lawsuits Consolidated in U.S. District Court

by Jeffrey S. Glassman

The Judicial Panel on Multidistrict Litigation has recently approved a motion to consolidate federal lawsuits filed against Pfizer Inc. due to Lipitor side effects. Lipitor is a widely-prescribed drug that was marketed to patients as a means of lowering cholesterol. Unfortunately, the drug has been linked to the development of Type 2 diabetes and patients who developed diabetes have sued the drug manufacturer.

The Judicial Panel On Multidistrict Litigation (JPML) has approved the consolidation of the cases before the Honorable Judge Richard M. Gergel, who is already presiding over 27 Lipitor cases. The Judge’s experience in hearing Lipitor cases over the course of the past year has prepared him to manage the mass tort litigation that the approved motion creates.
Continue reading

February 26, 2014

Abbot Labs Accused of Hiding Testosterone Replacement Therapy Dangers

by Jeffrey S. Glassman

AndroGel is a topical hormone marketed to men experiencing complications from low levels of natural testosterone. AndroGel was heavily promoted by Abbott Laboratories and AbbVie Inc., with the companies selling the product through testimony from retired professional athletes. Abbott Laboratories and AbbVie Inc. also provided statistics and fed positive reports to the press, showing that Low-T was a widespread problem that AndroGel could solve.

Unfortunately, the positives of this topical treatment may have been exaggerated and the risks downplayed. Men who used AndroGel now claim to have suffered serious injuries as a result of complications they were unaware of when they used the testosterone replacement drug. Lawsuits have been filed to pursue a claim for damages, and other victims who were harmed by AndroGel should contact a products liability lawyer for help pursuing their own claims.
Continue reading

February 24, 2014

Major Chicken Provider Shut Down for Unsanitary Conditions

by Jeffrey S. Glassman

Foster Farms, a chicken processing plant in California, didn’t open re-open its doors last week after it was shut down by officials because of an alleged cockroach infestation, report NBC. Officials with the company state that they needed more time to address the problem before opening in good faith.

Officials with the U.S. Department of Agriculture shut down the plant last week after allegedly finding live cockroaches for the fifth time in the last five months. These same officials lifted the suspension, but officials with the company said that they would need to remain closed longer. There is no schedule for re-opening at this point.

Our food poisoning attorneys understand Foster Farms was already closed because of two salmonella food poisoning outbreaks last year. The outbreaks were related to the company’s chicken, including a current outbreak that has already sickened more than 200 people in 23 states, as well as Puerto Rico. Even with this outbreak and the illnesses, as well as a federal shutdown threat, Foster Farms kept its doors open and has neglected to issue any recalls.
Continue reading

February 22, 2014

Actos Bladder Cancer Bellwether Trial Begins

by Jeffrey S. Glassman

A federal jury is preparing to hear a bellwether case regarding the alleged cancer-causing diabetes drug Actos, manufactured by Asia’s largest drugmaker, Takeda Pharmaceuticals.

The plaintiff in Terrence Allen et ux. v. Takeda Pharmaceuticals North America Inc. et al alleges damages in excess of $75,000 after he says he developed bladder cancer because of his use of the drug for treatment of Type II diabetes. The drug was approved by the FDA for U.S. sales in 1999, but the plaintiff alleges the drugmaker knew then that the drug, with a brand name of Pioglitazone, caused bladder cancer. This risks, it is alleged, were downplayed to federal regulators and actively concealed from doctors and patients.

The trial, one of the first of some 3,000 cases pending across the country, is taking place in the U.S. District Court, Western District of Louisiana (Lafayette). Other plaintiffs are watching closely, as the outcome here could affect those in thousands of other cases. As our Boston Actos bladder cancer attorneys understand it, the trial, expected to span about six weeks, has gotten off to a rough start for the defense.
Continue reading

February 20, 2014

Maine’s Relaxed Import Drug Law & Risk of Dangerous Drugs

by Jeffrey S. Glassman

Concerns regarding defective drugs in New England are heightened, following Maine’s recent passage of a law that allows residents there to import prescription drugs from overseas.

The policy’s staunch critics include the Pharmaceutical Research and Manufacturer’s of America, the Maine Pharmacy Association and big-name drug manufacturers such as Pfizer and Johnson & Johnson. The problem, they say, is that when drugs are imported from overseas, quality control standards may not apply.

Part of it, of course, is that, undoubtedly, cheaper prescription drugs from other countries cut into profits. But our defective drug lawyers in Boston believe these firms do have a point.
Continue reading